Glucotrack Expands its Clinical Advisory Team

David S. Hirsh, M.D., has joined Glucotrack Inc.’s clinical advisory team as medical director – Cardiology, providing strategic leadership for clinical and educational initiatives for the company’s Continuous Blood Glucose Monitor (CBGM).

“We are delighted to welcome Dr. Hirsh to the Company in this pivotal role supporting our clinical development program,” Glucotrack President/CEO Paul V. Goode, Ph.D., said. “Dr. Hirsh’s expertise in interventional cardiology procedures directly supports our CBGM’s unique intravascular placement—an approach that builds on proven cardiovascular design concepts and outpatient procedures to deliver accurate, real-time glucose readings. As we advance through our clinical trials, including our long-term OUS early feasibility study and upcoming U.S. pilot study, his clinical oversight will be valuable for appropriate site selection, physician education and protocol compliance.”

Dr. Hirsh has extensive cardiology and electrophysiology experience. Since early 2025, he has been a cardiac electrophysiologist at Harbin Clinical Cardiology Rome (in Georgia). Before Harbin Clinical, Dr. Hirsh was an associate professor of Medicine in the Division of Cardiology at Emory University School of Medicine, as the director of Clinical Cardiac Electrophysiology at Grady Memorial Hospital, where he started the electrophysiology laboratory at Atlanta’s large public hospital, and as clinical cardiac electrophysiologist at the Atlanta VA Medical Center.

Dr. Hirsh earned his medical degree from Albert Einstein College of Medicine at Yeshiva University and completed his residency and fellowships at the New York University Medical Center, where he was appointed the Chief Fellow in internal medicine, cardiovascular disease, and clinical cardiac electrophysiology during his training.

“I am honored to join Glucotrack during this exciting phase of clinical development,” Dr. Hirsh stated. “Glucotrack’s approach of using proven cardiovascular implantation techniques for continuous blood glucose monitoring represents a breakthrough in diabetes care and I look forward to applying my cardiology expertise to help advance this technology through clinical trials and toward commercialization.”

Dr. Hirsh strengthens Glucotrack’s clinical leadership team as the company progresses through multiple clinical milestones. His role will also be critical for developing education and training programs for cardiac interventionalists and for engaging with the endocrinology community on coordinated clinical care for people living with diabetes.

Glucotrack’s CBGM is a long-term implantable system with no wearable component, designed for up to three years of continuous, accurate blood glucose monitoring, offering a more convenient and less intrusive glucose monitoring solution. The CBGM measures glucose directly from blood, unlike traditional continuous glucose monitoring systems which measure glucose from interstitial fluid. Thus, it aims to provide real-time readings without the lag time typically associated with interstitial glucose measurements.

Glucotrack, Inc. designs, develops, and commercializes technologies for people with diabetes. The company is currently developing a long-term implantable continuous blood glucose monitoring system for people living with diabetes. The Glucotrack CBGM is an investigational device and is limited by U.S. law to investigational use.